Tags

Type your tag names separated by a space and hit enter

Drug Insight: renal indications of calcimimetics.
Nat Clin Pract Nephrol. 2006 Jun; 2(6):316-25.NC

Abstract

Calcimimetics suppress the secretion of parathyroid hormone by sensitizing the parathyroid calcium receptor to serum calcium. Cinacalcet (Sensipar/Mimpara), Amgen Inc., Thousand Oaks, CA), the first-in-class calcimimetic agent approved for treatment of secondary hyperparathyroidism in dialysis patients, is, in association with higher dose of a calcium-based oral phosphate binder, a well-tolerated and effective alternative to standard treatments such as vitamin D derivatives in association with a non-calcium-based oral phosphate binder. Here, we present an overview of evidence in support of this assertion. We extend our discussion to encompass other indications for calcimimetics -- secondary hyperparathyroidism in predialysis chronic kidney disease patients, hypercalcemic hyperparathyroidism in renal transplant recipients, primary hyperparathyroidism, and hypercalcemia associated with parathyroid carcinoma -- as well as providing guidance on optimal usage of this drug.

Authors+Show Affiliations

Department of Nephrology Internal Medicine, Amiens University Hospital, Jules Verne University of Picardy, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16932453

Citation

Shahapuni, Irina, et al. "Drug Insight: Renal Indications of Calcimimetics." Nature Clinical Practice. Nephrology, vol. 2, no. 6, 2006, pp. 316-25.
Shahapuni I, Monge M, Oprisiu R, et al. Drug Insight: renal indications of calcimimetics. Nat Clin Pract Nephrol. 2006;2(6):316-25.
Shahapuni, I., Monge, M., Oprisiu, R., Mazouz, H., Westeel, P. F., Morinière, P., Massy, Z., Choukroun, G., & Fournier, A. (2006). Drug Insight: renal indications of calcimimetics. Nature Clinical Practice. Nephrology, 2(6), 316-25.
Shahapuni I, et al. Drug Insight: Renal Indications of Calcimimetics. Nat Clin Pract Nephrol. 2006;2(6):316-25. PubMed PMID: 16932453.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Drug Insight: renal indications of calcimimetics. AU - Shahapuni,Irina, AU - Monge,Matthieu, AU - Oprisiu,Roxana, AU - Mazouz,Hakim, AU - Westeel,Pierre-François, AU - Morinière,Philippe, AU - Massy,Ziad, AU - Choukroun,Gabriel, AU - Fournier,Albert, PY - 2005/09/08/received PY - 2006/02/21/accepted PY - 2006/8/26/pubmed PY - 2006/9/29/medline PY - 2006/8/26/entrez SP - 316 EP - 25 JF - Nature clinical practice. Nephrology JO - Nat Clin Pract Nephrol VL - 2 IS - 6 N2 - Calcimimetics suppress the secretion of parathyroid hormone by sensitizing the parathyroid calcium receptor to serum calcium. Cinacalcet (Sensipar/Mimpara), Amgen Inc., Thousand Oaks, CA), the first-in-class calcimimetic agent approved for treatment of secondary hyperparathyroidism in dialysis patients, is, in association with higher dose of a calcium-based oral phosphate binder, a well-tolerated and effective alternative to standard treatments such as vitamin D derivatives in association with a non-calcium-based oral phosphate binder. Here, we present an overview of evidence in support of this assertion. We extend our discussion to encompass other indications for calcimimetics -- secondary hyperparathyroidism in predialysis chronic kidney disease patients, hypercalcemic hyperparathyroidism in renal transplant recipients, primary hyperparathyroidism, and hypercalcemia associated with parathyroid carcinoma -- as well as providing guidance on optimal usage of this drug. SN - 1745-8323 UR - https://wwww.unboundmedicine.com/medline/citation/16932453/Drug_Insight:_renal_indications_of_calcimimetics_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=16932453.ui DB - PRIME DP - Unbound Medicine ER -